
Hepatocellular carcinoma is the sixth most common cancer worldwide. In the majority of cases, there is evidence of existing chronic liver disease from a variety of causes including viral hepatitis B and C, alcoholic liver disease and nonalcoholic steatohepatitis. Identification of the signalling pathways used by hepatocellular carcinoma cells to proliferate, invade or metastasize is of paramount importance in the discovery and implementation of successfully targeted therapies. Activation of Wnt/β-catenin, Notch and Hedgehog pathways play a critical role in regulating liver cell proliferation during development and in controlling crucial functions of the adult liver in the initiation and progression of human cancers. β-catenin was identified as a protein interacting with the cell adhesion molecule E-cadherin at the cell-cell junction, and has been shown to be one of the most important mediators of the Wnt signalling pathway in tumourigenesis. Investigations into the role of Dkk1 in hepatocellular carcinoma have demonstrated controversial results, with a decreased expression of Dkk1 and soluble frizzled-related protein in various cancers on one hand, and as a possible negative prognostic indicator of hepatocellular carcinoma on the other. In the present review, the authors focus on the Wnt/β-catenin, Notch and Sonic Hedgehog pathways, and their interaction with Dkk1 in hepatocellular carcinoma.

Key words: β-catenin; Dickkopf-1; Hepatocellular carcinoma; Notch; Sonic Hedgehog; Wnt

MOLECULAR SIGNALLING IN HEPATOCELLULAR CARCINOMA

In the majority of cases of hepatocellular carcinomas (HCCs), there is evidence of existing chronic liver disease as a predisposing factor (1,2). Almost all pathological liver conditions encompassing fibrosis and cirrhosis have been shown to lead with the development of HCC, including chronic viral hepatitis B and C, alcoholic liver disease, metabolic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis and primary sclerosing cholangitis (3). As a consequence of hepatocyte injury, and in response to released inflammatory cytokines and oxidative stress, stellate cells and portal fibroblasts undergo activation and myofibroblastic transformation, leading to the development of fibrosis and, eventually, cirrhosis (4). Hepatocytes proliferate to regenerate the injured liver, albeit in states of continuing inflammation and oxidative stress, and in the presence of inciting agents capable of direct or indirect genotoxic damage.

The development of successfully targeted therapies for HCC is dependent on the identification of signalling pathways used by tumour cells to proliferate, invade or metastasize during the progress of tumour growth. Important epigenetic changes have been discovered in HCC including hypermethylation of p16 and E-cadherin. Chromosomal losses, deletions or gains affecting tumour suppressor genes have been found at different chromosome arms. Moreover, loss of heterozygosity has been identified on chromosomes 17p (TP53), 13q (RB1), 16p (AXIN1), 9p (CDKN2A) and 16q (IGF2R) (5). Additional genetic mechanisms in the development of HCC include mutations in genes such as p53 (6,7), CTNNB1 (8) and PTEN (9). As a result, several signalling pathways have been discovered and these include the hepatocyte growth factor/MET, epidermal growth factor receptor/Ras/mitogen-activated protein kinase, Wnt/β-catenin, PI3K/Akt and insulin-like growth factor signalling cascades, Notch and Hedgehog (HH) (10). Although most of the signalling pathways have independent...
many important functions of the liver, such as ammonia and nitrogen metabolism, and bile acid homeostasis, it helps in the recovery from metabolic injury and oxidative stress. The Wnt/β-catenin controls tissue development in embryos and tissue maintenance in adults in cell proliferation, epithelial-mesenchymal transitions and cell death. Activation of the Wnt pathway leads to uncontrolled cell proliferation and growth, promoting the development of multiple types of cancer (20,21).

Activation of the Wnt pathway is through the binding of secreted growth factors of the Wnt family to Frizzled (Fz) receptors at the surface of target cells. Intracellular signalling of Wnt ligands uses two different signal transduction pathways, the 'canonical pathway', which involves regulation of the protein β-catenin, and the 'noncanonical pathway', which is independent of β-catenin. Although the two Wnt pathways have been studied separately, there is evidence indicating cross-talk between the two pathways. Upregulation of Wnt ligand expression, increased expression of the Fz receptors, methylation of secreted Fz-related proteins (sFRPs), mutations in axin1 and tyrosine-phosphorylation-dependent activation of β-catenin are responsible for activation of β-catenin (22,23). In HCC induced by hepatitis B virus, canonical Wnt3 and downstream β-catenin target genes were upregulated. This upregulation of the Wnt pathway by Wnt3 was mediated by Fz-7 receptor (FZD7), and activation of the Wnt pathway in a Wnt3-overexpressing cell line was abolished by small interfering RNA-mediated FZD7 knockdown (24).

Canonical Wnt signalling is more frequently activated in well-differentiated HCC cells, while noncanonical Wnt signalling is more frequently activated in poorly differentiated HCC. Expression of the noncanonical Wnt5a, which is known to inhibit canonical Wnt signalling, was increased in poorly differentiated HCC cell lines (25). When Wnt5a is expressed in a well-differentiated cell line that normally shows high canonical Wnt activation due to an activating β-catenin mutation, repression of canonical Wnt signalling is found. Combining the upregulation of Wnt3 in canonical pathway and Wnt5a in the noncanonical pathway, we can assume that the two Wnt pathways are selectively activated or repressed based on the differentiation status of HCC cells, and have complementary roles in the hepatocarcinogenesis. Canonical Wnt signalling contributes to tumour initiation and noncanonical Wnt signalling to tumour progression (26). In addition to Wnt5a, the noncanonical Wnt11 was recently found to have a role as a cancer suppressor, providing further proof of a complex interplay between the canonical and noncanonical Wnt signalling pathways. Expression levels of Wnt11 were lower in human HCC tumors compared with adjacent liver tissue, and overexpression of Wnt11 reduced cell motility and migration of liver cancer cell lines via activation of Rho kinase (27).

**CANONICAL WNT SIGNALLING AND β-CATENIN ACTIVATION PATHWAY**

As already referred to, the Wnt genes encode a large family of secreted glycoproteins that act as extracellular signalling molecules, initiating a signalling cascade, which results in activation of β-catenin. In canonical Wnt signalling, β-catenin plays the key role in transduction signalling. Its concentration in the cytoplasm of unstimulated cells is kept very low through phosphorylation by two kinases, casein kinase 1 and GSK3β, functioning in a multiprotein complex including the products of two tumour suppressor genes, the APC and AXIN1 genes. Phosphorylated β-catenin is then ubiquitinated, resulting in its proteasomal degradation. Accessibility of the Wnt ligands to the Fz receptors is controlled by different Wnt inhibitors present in the extracellular compartment that prevent illegitimate β-catenin transduction signalling. In the activation state, when Wnt ligands bind to FZ-low-density lipoprotein receptor-related protein 5/6 (FZ-LRP5/6) receptor complexes, a series of events preventing the cytosolic degradation of β-catenin occurs, inducing β-catenin accumulation. The complex formed by Wnt-FZ-LRP5/6 is followed by recruitment of the scaffolding protein Dishevelled, phosphorylation of LRP5 and recruitment of
the axin degradation complex, preventing phosphorylation of β-catenin, its stabilization and cytoplasmic accumulation. The subsequent translocation of β-catenin to the nucleus and formation of a complex with the T-cell factor/lymphoid-enhancer factor (TCF/LEF) transcription factors activates target gene expression (Figure 2). A potential crosstalk among various liver cells expressing different Wnt ligands is highly possible and lipoprotein particles and glycans can act as vehicles for the movement of Wnt ligands to distant sites, suggesting that intracellular Wnt signalling can be modulated by systemic signals (28,29).

**β-CATENIN MUTATION ACTIVATION IN HCC**

The mechanism of β-catenin activation in HCC is due to mutations in the β-catenin gene (CTNNB1), which have been noted in approximately 20% to 40% of all cases (30-33). Mutations have also been reported in the components of the degradation complex of β-catenin including axin1 in approximately 3% to 16% (30,35-37) and axin2 in approximately 3% of all HCC cases (37). These proteins form an α-catenin ‘degradation complex,’ allowing in this way the phosphorylated β-catenin to be recognized by β-TrCP, targeted for ubiquitination, and degraded by the proteasome (38,39). In the absence of the Wnt signal, TCF would act as a repressor of Wnt target genes by binding their promoter and enhancer regions, with sequence specificity and preventing their expression; when in the presence of Wnt signalling, the β-catenin degradation process is disrupted and it accumulates in the cytoplasm and translocates to the nucleus. In the nucleus, β-catenin binds to TCF homologues and LEF, resulting in alteration of the transcriptional machinery, removing the repression and activation of the target genes. Nuclear levels of β-catenin are normally moderated by interaction with nuclear APC and axin2, which shuttle β-catenin back into the cytoplasm, and the mutation of these promote β-catenin stabilization, demonstrated in many different cancers (40). Additional mechanisms have also been described and include overexpression of FZD7 (41,42), inactivation of GSK3β (43), methylation of sFRP1 and β-catenin activation by receptor tyrosine kinases (44).

Immunostaining patterns of β-catenin and β-catenin-associating cell adhesion molecules in HCCs were first demonstrated by Ihara et al (45). de La Coste et al (46) demonstrated that one-quarter of human HCCs had β-catenin point mutations and deletions that led to aberrant β-catenin activation (46). In addition, β-catenin mutations were also found in hepatoma cell lines and in a subset of transgenic mouse lines of HCC. Furthermore it has been demonstrated that point mutations at specific serine and threonine residues in exon 3 are important for the aberrant activation of β-catenin in a subset of human HCCs (47). Mice expressing a mutated form of β-catenin harbouring a mutation at the serine-45 residue in exon 3 did not develop spontaneous tumours, but had increased susceptibility to developing HCCs on exposure to the carcinogen diethylnitrosamine (48). Up to 90% of HCCs have aberrant β-catenin activation in the absence of activating mutations in the CTNNB1 gene. In these tumours, there are additional mechanisms that comprise the upregulation of Wnt ligand receptors; methylation of sFRPs; mutations in components of the β-catenin destruction complex (axin1); and tyrosine-phosphorylation-dependent activation of β-catenin. All of the above are responsible for aberrant activation of β-catenin (49-51). In support of a direct role of β-catenin in hepatocarcinogenesis was the finding that aberrant activation of β-catenin by inactivating its suppressor APC led to the spontaneous development of HCCs in mice (52). On the other hand, mice overexpressing either mutated or nonmutated forms of β-catenin did not develop spontaneous tumours (53-55). Interestingly, mice with liver-specific disruption of β-catenin also showed increased diethylamino-induced hepatocarcinogenesis via increased oxidative stress and hepatocyte proliferation resulting from PDGFRα/Pik3ca/Akt activation and c-Myc over-expression (56).
which promotes the degradation of β-catenin (76). It has been reported that the Wnt/PCP pathway in Drosophila regulates the polarization within the plane of epithelium, which is perpendicular to the apical-basal axis (77). When stimulated by Wnt5a or Wnt11, this pathway diverges following the activation of Dishevelled and transduces signals that activate Rho and Rac, which in turn activate Rho-associated kinase and JNK, respectively. An overview of canonical and noncanonical Wnt signalling pathway is shown in Figure 3.

**DICKKOPF-1 AND WNT SIGNALLING**

As well as an increased expression of Wnt proteins, the extracellular ligands of the Wnt/β-catenin pathway, a decreased expression of Dickkopf (Dkk)-1 and soluble FRP, which are inhibitors of Wnt signalling, have been observed in various cancers (78). sFRP1, sFRP2, sFRP3, sFRP4, sFRP5, Wnt inhibitory factor 1, Dkk1, Dkk2, Dkk3 and Dkk4 consist of secreted-type Wnt signalling inhibitors. sFRP family members and Wnt inhibitory factor 1 are Wnt antagonists that inhibit Wnt binding to FZD family receptors, when Dkk family members demonstrate interaction with LRP5/LRP6 coreceptor and initiate its endocytosis, resulting in the inhibition of the formation of the Wnt-FZ-LRP5/LRP6 complex for the canonical Wnt signalling (79). Epigenetic silencing of Dkk1, among other genes, appears to take place in premalignant tissues associated with chronic inflammation or in human cancer (80,81).

Dkk1 has been shown to control Wnt signalling by its binding to the LRP receptor and blocking Wnt from binding to the receptor complex. Additionally, the expression of Dkk-1 in HeLa cells has suggested that the Dkk1 gene acts as a functional suppressor of cell transformation and tumorigenic growth (82-84). A possible role for Dkk1/Wnt/β-catenin cascade in the metastasis of hepatoma cells was reported by Qin et al (85), who demonstrated that overexpression of Dkk1 was able to downregulate β-catenin, c-Myc, cyclin D1, proliferating cell nuclear antigen and B-cell lymphoma 2 and, also, it inhibited the migration of M-H7402 cells. They concluded that downregulation rather than activation of Dkk1 expression may influence cell growth, migration and malignancy, suggesting that the β-catenin pathway may contribute to the metastasis of the hepatoma cells. It was also shown that Dkk1 downregulated the expression of c-Myc, which is active in a variety of tumours and its increased expression is frequent in primary HCC. Previously, Kwack et al (86) had reported findings highlighting that Dkk-1 is expressed in some HCC cell lines and its forced expression caused growth inhibition. Contradictory to this, the overexpression of Dkk1 resulted in reduced cell adhesion and increased cell migration, which play a central role in tumour promotion. In recent reports it has also been demonstrated that serum and tissue Dkk1 levels increased in a stepwise manner in multistep hepatocarcinogenesis, with Dkk1 playing a functional role in cell migration, invasion and tumour growth (87). Other authors had already demonstrated that HCC patients with high Dkk1 expression and cytoplasmic/nuclear β-catenin accumulation had very poor prognosis (88). Recently, a large multicentre study concluded that Dkk1 could complement measurement of AFP in the diagnosis of HCC, and also improve the identification of patients with AFP-negative HCC and assist in distinguishing HCC from nonmalignant chronic liver diseases (89).

**THE Hh SIGNALLING PATHWAY AND HCC**

It is well documented that signalling pathways other than Wnt/β-catenin have central role in the development of HCC. These included the Hh signalling pathway, which has been shown to play a key role in the genesis of different malignancies, as well as in other processes, including embryogenesis and tissue repair (90), which is managed via Hh-dependent autocrine/paracrine mechanisms controlling the size and localization of Hh-responsive cell populations (91-93). Moreover, possible interaction and cross-talk between Wnt/β-catenin and Hh signalling in liver cancer would be expected but has not yet been clarified.

Of the three known mammalian Hh ligands, Sonic Hh (Shh), Indian Hh and Desert Hh, Shh is considered to be the most widely expressed and most potent (94). In addition to playing a critical role in organizing cell growth and differentiation during embryonic tissue patterning (95-96), dysregulation of the Hh pathway has been implicated in the development of human malignancies of the gastrointestinal tract, including that of the pancreas and as well as HCC (97-101). Transcriptional upregulation of Hh ligands and epigenetic silencing of Hh interacting protein 1/Hhh interacting protein gene with encoding of the Hh inhibitor, would lead to Hh signalling, in this way promoting epithelial proliferation and carcinogenesis (101).

On the other hand, Hh signalling has been shown to inhibit epithelial proliferation in the intestine because it has a negative effect on the canonical Wnt signalling pathway (102). Additionally, Shh has been highlighted as responsible for pancreatic ductal adenocarcinoma cell proliferation, epithelial-mesenchymal transition and maintenance of cancer stemness (103). Reports have also shown Hh pathway activity in cholangiocarcinoma and hepatoblastoma cell lines and also subgroups of patients with HCC (104,105). Blockage of the growth of hepatoblastoma cells in culture has also been demonstrated by Hh pathway inhibitors, adding to the hypothesis that inappropriate activation of Hh signalling may have a key role in hepatocarcinogenesis. Hh-responsive cells appear to develop in the context of liver cirrhosis, which would add to the procarcinogenic role of the Hh pathway (106).

Shh is cleaved by proteolysis and produces two secreted proteins, a 19 kDa N-terminal protein that mediates all signalling activities and a 25 kDa C-terminal protein that possesses protease activity (107-109). The Shh signalling pathway (Figure 4) involves two transmembrane proteins, Patched (Ptc), a 12-transmembrane protein, and Smoothened (Smo), a seven-transmembrane protein with G-protein-coupled receptors, which is the signalling component of the Shh-receptor complex (110). Ptc binds with SHh, whereas Smo acts as a signal transducer. In the absence of ligands, Ptc interacts with and inhibits Smo. This interaction activates a transcriptional repressor such as Gli protein. In the presence of ligands, the binding of Shh to Ptc prevents the inhibition of Smo, activating the transduction pathway; the interaction of Ptc and Smo is altered and Smo is no longer inhibited. The Gli protein may then enter the nucleus and function as a transcriptional activator. To regulate the Shh signalling pathway during the development of the vertebrate central nervous system, either inhibition of Gli proteins...
SHH SIGNALLING

It has been suggested that platelet-derived growth factor, an injury-related cytokine released during the adult liver repair, can activate hepatic stellate cells and produce Hh ligands, with the latter inducing Hh signalling and, thus, resulting in the growth of septal myofibrolastic-hepatic stellate cell populations, but also neighbouring Hh-responsive cells, including certain types of epithelial progenitors (116-118). Mature hepatocytes are not Hh responsive; however, a progressive enrichment of the hepatic microenvironment with Hh ligands during the process of liver injury provides survival benefit for the Hh-responsive cells, which include myofibroblastic and progenitor cells. As Hh signalling subsides, the differentiation of Hh-responsive cells would be promoted by other factors, leading to reaccumulation in the liver of the original, Hh-responsive populations, of liver fibrosis and HCC (118).

The Hh pathway plays key roles in several cellular events as well as cell proliferation (119); namely, inhibition of apoptosis (120), invasiveness and metastasis (121,122). Activation of the SHH pathway appears to be important on both the development and the progression of HCC (123,124). Ptc and Gli-1 are downstream target genes of the Hh pathway; thus, their transcript indicates Hh signalling activation. Chen et al (125) found that SHH signal pathway activation was associated with tumour size, capsular invasion and vascular invasion. In another study, Chen et al (126) also demonstrated that SHH pathway induced cell migration and invasion through focal adhesion kinase/Akt signalling-mediated matrix metalloproteinase-2 and matrix metalloproteinase-9 production and activation in liver cancer. Tada et al (127) regarded the overexpression of Smo or SHH as being positive regulators and the major trigger for the activation of this signalling pathway, mediating c-myc overexpression and playing a critical role in hepatocarcinogenesis. Ptc-1 activation predisposes a cell to proliferative and activates Smo, an intracellular substrate that migrates to the cellular membrane. At the cellular membrane, the activated Smo triggers the downstream transcription of Gli-1 proteins (128-129). Aberrant activation of the SHH pathway leads Gli-1 into the nucleus to promote gene transcription and to maintain the biological behaviours of cancer cells. Activation of the SHH pathway may also occur in different stages of the same cancer. Thus, Huang et al (130) suggested that the activation occurs in the early stage of HCC, whereas Thayer et al (131) considered that Hh is both a late mediator as well as an early mediator in pancreatic carcinogenesis.

NOTCH SIGNALLING PATHWAY

The Notch signalling pathway is a highly conserved signalling pathway, plays a key role in cell-cell communications and regulates multiple cell differentiation processes during embryonic development and throughout adulthood (132,133). In the liver, Notch coordinates biliary fate and differentiation processes during embryonic development and throughout adulthood (132,133). In the liver, Notch physically interacts with β-catenin and modulates Wnt signalling by negatively regulating β-catenin activity in flies (154) exhibiting the antagonism of Wnt signalling by uncleaved Notch without involving Notch ligands and CSL. In addition, Notch functions both
as a membrane transcription factor and as membrane-bound regulator by lowering levels of the transcriptionally active form of β-catenin (155-157). This form of β-catenin is dephosphorylated at Ser37 and Thr41 and normally constitutes a small fraction of total β-catenin (158). In mammalian stem and progenitor cells, notch levels are inversely correlated with active β-catenin (155,159). The RAM domain, which is the CSL-binding domain of Notch, is required for the physical interaction and regulation of active β-catenin (155,160). Membrane Notch regulation of active β-catenin occurred independent of GSK3β, (161,162), and genetic analyses revealed that membrane Notch was able to downregulate increased β-catenin activity resulting from GSK3β loss of function (154). On the other hand, a recent study suggested that axin and APC participate in this regulation by modulating endocytosis and trafficking of membrane Notch (163).

CONCLUSION
Understanding the complex signalling pathway and the pathophysiology of hepatocarcinogenesis is of paramount importance for the identification of specific targets for therapeutic intervention. Wnt/β-catenin, Hh and Notch signalling pathways act in controlling progenitor cell growth and promote liver inflammation and fibrogenic repair and, thereafter, hepatocarcinogenesis. Possible cross-talk between different signalling pathways in liver cancer development could lead in a combination of treatment agents and increase the efficacy of therapeutic interventions. Further studies are needed to explore the use of small molecules, targetted particularly to the Wnt/β-catenin Hh and Notch pathways and to clarify exact mechanisms of cross-talk between these pathways.

DISCLOSURES: The authors have no financial disclosures or conflicts of interest to declare.

REFERENCES


